Bio News
Caldera has listed on Nasdaq through a reverse merger with Synlogic and raised $278 million in a private placement. The company’s bispecific antibody CLD-423 targets IL-23p19 and TL1A and demonstrated safety and 80% subcutaneous bioavailability in a phase 1 trial. The funding will support phase 2 trials in ulcerative colitis and Crohn disease as the company moves to rapidly generate clinical evidence.
BIOBOOK TEAM
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
